Keywords
androgenetic alopecia
alopecia areata
minoxidil
finasteride
JAK inhibitors
US market
telemedicine
telepharmacy
combination therapy
How to Cite
Abstract
Alopecia is a common chronic condition that has a significant medical and social impact, including on the psychological comfort and quality of life of patients. The most common forms are androgenetic and alopecia areata. Treatment includes both drugs approved by the US Food and Drug Administration (FDA) and cosmetics without regulatory approval. Despite progress in pharmacotherapy, the problem of complete and stable hair restoration remains relevant. The aim is to comprehensively analyze modern drugs for the treatment of alopecia used in the US, taking into account their clinical and pharmacological efficacy, safety, economic availability, regulatory status and market development prospects. An analytical review was conducted using FDA data, scientific publications, official sources of manufacturers, price aggregators (GoodRx, Drugs.com). The objects of analysis were six FDA-approved drugs (minoxidil, finasteride, triamcinolone, clobetasol, baricitinib, ritlecitinib) and one cosmetic product without FDA approval (HydraFacial Keravive Peptide Complex). Clinical-pharmacological, documentary, regulatory, comparative, marketing and SWOT analysis of market trends were applied. It was found that minoxidil and finasteride remain the most affordable and have a significant evidence base of effectiveness. JAK inhibitors (baricitinib, rituximab) demonstrate high clinical results in patients with alopecia areata. However, their cost significantly exceeds the average level of financial capabilities of most patients. Corticosteroids (triamcinolone, clobetasol) retain an important role in the treatment of inflammatory forms of alopecia. Cosmetic products, in particular Keravive Serum, are used as additional methods to improve the condition of the scalp and stimulate hair growth. SWOT analysis revealed the market strengths (availability of drugs with proven efficacy), weaknesses (high cost of innovative drugs), opportunities (development of combination therapy, telemedicine and telepharmacy) and threats (regulatory restrictions, economic barriers to accessibility). The market for alopecia treatment in the US is characterized by a combination of traditional and innovative products. The most promising areas of development are the introduction of innovative drugs (in particular, JAK inhibitors), combined treatment regimens, as well as expanding access to therapy using telemedicine, telepharmacy and online pharmacies. To increase the effectiveness of treatment, individualization of therapeutic strategies is necessary, taking into account the clinical form of alopecia, the patient's financial capabilities and the prognosis for response to treatment.
References
1. Wendy S. Alopecia. Hartford Dermatology Associates. 2025. URL: https://www.msdmanuals.com/uk/professional/dermatologic-disorders/hair-disorders/alopecia
2. Salava A. Guideline 00291. Hair loss. DUODECIM Medical Publications. 15.02.2018. URL: https://guidelines.moz.gov.ua/documents/3175
3. Alopecia Areata. Cleveland Clinic. URL: https://my.clevelandclinic.org/health/diseases/12423-alopecia-areata
4. Wendy S. Alopecia Areata. Hartford Dermatology Associates. 2024. URL: https://www.msdmanuals.com/uk/professional/dermatologic-disorders/hair-disorders/alopecia-areata
5. Klymyshyna S. O., Tsyznetska A. V., Rachkevych L. V. Pharmaceutical Cosmetology. Ternopil: Volya, 2009. 367 p..
6. Cosmetics Laws & Regulations. FDA. URL: https://www.fda.gov/cosmetics/cosmetics-guidance-regulation/cosmetics-laws-regulations
7. Hair loss. Mayo Clinic. URL: https://www.mayoclinic.org/diseases-conditions/hair-loss/symptoms-causes/syc-20372926
8. Borysyuk I.Yu., Fizor N.S., Valivodz I.P., Akisheva A.S. Technology of medical and cosmetic products: a textbook. Odesa, ONMedU, 2020. 52 p..
9. FDA – The official U.S. Food and Drug Administration website. URL: https://www.fda.gov/
10. Shapovalova V. Telemedicine and Telepharmacy in Modern Healthcare: Innovations, Medical Technologies, Digital Transformation. SSP Modern Pharmacy and Medicine. 2025. Vol. 5. No. 3. P. 1–19. DOI: https://doi.org/10.53933/r7f5xj91
11. Shapovalov V. Multidisciplinary study of medical errors in the system of legal relations between "Doctor-Patient-Pharmacist-Advocate" during the circulation of drugs. SSP Modern Pharmacy and Medicine. 2023. Vol. 3. No. 2. P. 1–11. DOI: https://doi.org/10.53933/sspmpm.v3i2.88
12. Rogaine® Men’s 5% Minoxidil Topical Solution. Rogaine. URL: https://www.rogaine.com/products/mens-rogaine-minoxidil-solution?variant=48456691384636
13. HydraFacial Keravive Peptide Complex Solution. HydraFacial. URL: https://hydrafacial.com/us/product/keravive/
14. Finasteride Prices. GoodRx. URL: https://www.goodrx.com/finasteride
15. Triamcinolone Prices. GoodRx. URL: https://www.goodrx.com/triamcinolone
16. Clobetasol Prices. GoodRx. URL: https://www.goodrx.com/clobetasol
17. Olumiant (baricitinib) Pricing. Drugs.com. URL: https://www.drugs.com/price-guide/olumiant
18. Litfulo (ritlecitinib) Official Website. Pfizer Inc. URL: https://www.litfulo.com/
19. Yan T., Wang T., Tang M., Liu N. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2024. Vol. 15. DOI: https://doi.org/10.3389/fphar.2024.1372810.
20. King B., Kwon O., Guttman-Yassky E., et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine. 2022. Vol. 386. No. 18. P. 1687–1699. DOI: https://doi.org/10.1056/NEJMoa2110343.
21. National Alopecia Areata Foundation. FDA-Approved JAK Inhibitors. 2024. URL: https://www.naaf.org/navigation-toolkit/fda-approved-jak-inhibitors/.
22. Nye J. Ritlecitinib and Baricitinib Have Similar Efficacy in Severe Alopecia Areata. Dermatology Advisor. 2024. URL: https://www.dermatologyadvisor.com/news/ritlecitinib-baricitinib-have-similar-efficacy-severe-alopecia-areata/.
23. Aceituno D., Fawsitt C. G., Power G. M. et al. Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2024. DOI: https://doi.org/10.1111/jdv.20372.
24. New York Post. New hair loss treatment being tested with paid volunteers. New York Post. 2025. February 7. URL: https://nypost.com/2025/02/07/health/new-hair-loss-treatment-being-tested-with-paid-volunteers/.
25. New York Post. Men going bald turn to "new Botox" for hair loss treatment. New York Post. 2025. March 27. URL: https://nypost.com/2025/03/27/lifestyle/men-going-bald-turn-to-new-botox-for-hair-loss-treatment/
26. Shapovalov V., Shapovalova V., Titarenko I. et al. Chronic pancreatitis: Pharmacotherapy, prescription of drugs, meta-analysis, latest digital medical technologies of quantum medicine. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2025. Vol. 54. No. 2. P. 475–489. DOI: https://doi.org/10.15446/rcciquifa.v54n2.117235. URL: https://revistas.unal.edu.co/index.php/rccquifa/article/view/117235
27. Shapovalov V.V. (Jr), Zbrozhek S.I., Shapovalova V.O., et al. Organizational and legal evaluation of availability of medicines’ circulation for cancer patients. Pharmacia. 2018. Vol. 65. No. 2. P. 17–22. URL: https://bsphs.org/wp-content/uploads/magazine/2018/2/Shapovalov.pdf
28. Nevzghoda O., Osyntseva A., Shapovalova V. et al. Optimization of pharmacotherapy for chronic pancreatitis: use of ABC/VED analysis in marketing and pharmacoeconomic studies. Proceedings of Shevchenko Scientific Society. Medical Sciences. 2025. Vol. 77. No. 1. P. 1–14. URL: https://doi.org/10.25040/ntsh2025.01.16
29. Nevzghoda O.A., Shapovalov V.V., Shapovalova V.O. et al. Optimisation of antibiotic selection: ABC and VED analysis of medicines against intracellular microorganisms. Tuberculosis, Pulmonary Diseases, HIV-infection. 2025. No. 3 (62). P. 68–79. DOI: http://doi.org/10.30978/TB2025-3-68.
30. Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 1. P. 1–13. URL: https://doi.org/10.53933/sspmpm.v2i1.37
31. Shapovalova V. The main changes in the ICD-11. Preprint. Version 1. 2024. DOI: https://doi.org/10.61829/7fvvxa57
32. Shapovalov (Jr.) V., Gudzenko A., Shapovalova V. et al. Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents. Pharmacia. 2017. Vol. 64. No. 3. P. 31–39. URL: https://bsphs.org/magazine/%D1%84%D0%B0%D1%80%D0%BC%D0%B0%D1%86%D0%B8%D1%8F-%D1%82%D0%BE%D0%BC-64-%D0%BA%D0%BD%D0%B8%D0%B6%D0%BA%D0%B0-3-2017/ URL: https://bsphs.org/wp-content/uploads/magazine/2017/3/Shapovalov.pdf
33. Peshuk, L. V., Bavika, L. I., Demidov, I. M. Technology of perfumery and cosmetic products. Kiev: Center for Educational Literature, 2007. 376 p.
34. Smoilovska G.P., Malyugina O.O., Mazulin O.V. Pharmaceutical technology: a basic guide for seminarians to take up visors in the transfer of the certification cycle for advanced qualifications for specialty "Zagalna Pharmacy". Part 4. Zaporizhzhya: ZDMU, 2018, 101 p.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Khrystyna Malaniuk (Author)